Moors & Cabot’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.29M | Sell |
15,025
-395
| -3% | -$141K | 0.23% | 95 |
|
|
2025
Q4 | $5.05M | Buy |
15,420
+359
| +2% | +$114K | 0.22% | 96 |
|
|
2025
Q3 | $4.25M | Sell |
15,061
-709
| -4% | -$206K | 0.19% | 106 |
|
|
2025
Q2 | $4.4M | Buy |
15,770
+320
| +2% | +$90.7K | 0.2% | 101 |
|
|
2025
Q1 | $4.81M | Sell |
15,450
-3,310
| -18% | -$977K | 0.24% | 86 |
|
|
2024
Q4 | $4.89M | Sell |
18,760
-1,689
| -8% | -$501K | 0.23% | 85 |
|
|
2024
Q3 | $6.59M | Sell |
20,449
-426
| -2% | -$139K | 0.33% | 64 |
|
|
2024
Q2 | $6.52M | Sell |
20,875
-919
| -4% | -$270K | 0.35% | 58 |
|
|
2024
Q1 | $6.2M | Buy |
21,794
+887
| +4% | +$260K | 0.34% | 63 |
|
|
2023
Q4 | $6.02M | Buy |
20,907
+204
| +1% | +$55.6K | 0.38% | 56 |
|
|
2023
Q3 | $5.56M | Buy |
20,703
+943
| +5% | +$235K | 0.38% | 58 |
|
|
2023
Q2 | $4.39M | Sell |
19,760
-498
| -2% | -$116K | 0.29% | 83 |
|
|
2023
Q1 | $4.9M | Buy |
20,258
+9
| +0% | +$2.21K | 0.34% | 68 |
|
|
2022
Q4 | $5.32M | Buy |
20,249
+1,225
| +6% | +$328K | 0.37% | 57 |
|
|
2022
Q3 | $4.29M | Buy |
19,024
+868
| +5% | +$210K | 0.33% | 74 |
|
|
2022
Q2 | $4.42M | Sell |
18,156
-251
| -1% | -$61.5K | 0.32% | 74 |
|
|
2022
Q1 | $4.45M | Buy |
18,407
+3,627
| +25% | +$833K | 0.27% | 84 |
|
|
2021
Q4 | $3.33M | Buy |
14,780
+1,095
| +8% | +$231K | 0.2% | 104 |
|
|
2021
Q3 | $2.91M | Buy |
13,685
+151
| +1% | +$34.8K | 0.18% | 119 |
|
|
2021
Q2 | $3.3M | Buy |
13,534
+133
| +1% | +$32.7K | 0.23% | 97 |
|
|
2021
Q1 | $3.33M | Sell |
13,401
-1,102
| -8% | -$263K | 0.25% | 91 |
|
|
2020
Q4 | $3.33M | Sell |
14,503
-12,652
| -47% | -$2.92M | 0.28% | 83 |
|
|
2020
Q3 | $6.9M | Sell |
27,155
-565
| -2% | -$140K | 0.65% | 29 |
|
|
2020
Q2 | $6.54M | Buy |
27,720
+1,658
| +6% | +$378K | 0.7% | 28 |
|
|
2020
Q1 | $5.28M | Sell |
26,062
-4,700
| -15% | -$1.03M | 0.77% | 25 |
|
|
2019
Q4 | $7.4M | Sell |
30,762
-688
| -2% | -$152K | 0.74% | 25 |
|
|
2019
Q3 | $6.09M | Buy |
31,450
+448
| +1% | +$86K | 0.67% | 28 |
|
|
2019
Q2 | $5.7M | Sell |
31,002
-299
| -1% | -$53.5K | 0.72% | 28 |
|
|
2019
Q1 | $5.94M | Sell |
31,301
-1,110
| -3% | -$212K | 0.81% | 23 |
|
|
2018
Q4 | $6.3M | Buy |
32,411
+412
| +1% | +$80.4K | 0.99% | 18 |
|
|
2018
Q3 | $6.63M | Buy |
31,999
+2,421
| +8% | +$477K | 0.81% | 23 |
|
|
2018
Q2 | $5.45M | Sell |
29,578
-1,535
| -5% | -$272K | 0.73% | 25 |
|
|
2018
Q1 | $5.3M | Sell |
31,113
-861
| -3% | -$158K | 0.7% | 24 |
|
|
2017
Q4 | $5.55M | Buy |
31,974
+1,986
| +7% | +$351K | 0.74% | 22 |
|
|
2017
Q3 | $5.6M | Buy |
29,988
+1,428
| +5% | +$253K | 0.81% | 20 |
|
|
2017
Q2 | $4.91M | Sell |
28,560
-1,286
| -4% | -$209K | 0.82% | 18 |
|
|
2017
Q1 | $4.89M | Buy |
29,846
+6,320
| +27% | +$1.05M | 0.82% | 20 |
|
|
2016
Q4 | $3.44M | Sell |
23,526
-2,517
| -10% | -$379K | 0.57% | 38 |
|
|
2016
Q3 | $4.35M | Buy |
26,043
+1,852
| +8% | +$313K | 0.73% | 24 |
|
|
2016
Q2 | $3.67M | Buy |
24,191
+241
| +1% | +$37.5K | 0.65% | 31 |
|
|
2016
Q1 | $3.58M | Buy |
23,950
+193
| +0.8% | +$28.7K | 0.65% | 28 |
|
|
2015
Q4 | $3.84M | Sell |
23,757
-228
| -1% | -$35.8K | 0.7% | 24 |
|
|
2015
Q3 | $3.32M | Buy |
23,985
+1,138
| +5% | +$179K | 0.61% | 35 |
|
|
2015
Q2 | $3.51M | Buy |
22,847
+5,236
| +30% | +$839K | 0.57% | 40 |
|
|
2015
Q1 | $2.82M | Buy |
17,611
+75
| +0.4% | +$11.8K | 0.47% | 52 |
|
|
2014
Q4 | $2.8M | Buy |
17,536
+4,100
| +31% | +$639K | 0.47% | 53 |
|
|
2014
Q3 | $1.89M | Buy |
13,436
+1
| +0% | +$131 | 0.32% | 79 |
|
|
2014
Q2 | $1.6M | Buy |
13,435
+907
| +7% | +$105K | 0.27% | 97 |
|
|
2014
Q1 | $1.54M | Buy |
+12,528
| New | +$1.52M | 0.39% | 67 |
|
Other funds holding AMGN
VCM
VPM
Moors & Cabot's AMGN Position: Q1 2026 in Review
Moors & Cabot reduced its Amgen (AMGN) stake by 2.6% in Q1 2026, selling an estimated $141K and leaving 15,025 shares worth $5.29M. The position accounts for 0.23% of the portfolio, ranked #95.
Moors & Cabot first reported a position in AMGN in Q1 2014 and has held it in 49 quarters since. The position peaked at $7.4M in Q4 2019. 3,131 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Moors & Cabot held 15,025 shares of Amgen worth $5.29M as of Q1 2026.
- Moors & Cabot sold 395 Amgen shares in Q1 2026, an estimated $141K.
- Amgen made up 0.23% of Moors & Cabot's portfolio in Q1 2026, its #95 holding.
- Moors & Cabot first reported a position in Amgen in Q1 2014 and has held it in 49 quarters since.
- Moors & Cabot's Amgen position peaked at $7.4M in Q4 2019.
- 3,131 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.